1.80
price down icon3.23%   -0.06
after-market After Hours: 1.82 0.02 +1.11%
loading

Immuneering Corp Stock (IMRX) Latest News

pulisher
Feb 10, 2025

Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC - MarketBeat

Feb 10, 2025
pulisher
Feb 07, 2025

Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Immuneering and Regeneron partner on lung cancer trial - Investing.com

Feb 06, 2025
pulisher
Feb 06, 2025

Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.80 - Defense World

Feb 06, 2025
pulisher
Feb 02, 2025

Immuneering Co. (NASDAQ:IMRX) Sees Large Decrease in Short Interest - MarketBeat

Feb 02, 2025
pulisher
Jan 30, 2025

Immuneering Corporation Unveils Promising Data for IMM-1-104 in Pancreatic Cancer, Plans for Expansion - HPBL

Jan 30, 2025
pulisher
Jan 28, 2025

Immuneering Corporation Shares Jump 55% Following Breakthrough Pancreatic Cancer Trial Results - HPBL

Jan 28, 2025
pulisher
Jan 23, 2025

Immuneering Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St

Jan 23, 2025
pulisher
Jan 17, 2025

Immuneering Corporation Stock Soars Following Promising Updates from Phase 2a Pancreatic Cancer Trials - HPBL

Jan 17, 2025
pulisher
Jan 16, 2025

Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1% - MarketBeat

Jan 16, 2025
pulisher
Jan 14, 2025

Immuneering Reports Positive Phase 2a Data for IMM-1-104 in Pancreatic Cancer, Expands Trial Plans - HPBL

Jan 14, 2025
pulisher
Jan 14, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Immuneering reports progress in pancreatic cancer trial - Investing.com

Jan 13, 2025
pulisher
Jan 13, 2025

Immuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer - Markets Insider

Jan 13, 2025
pulisher
Jan 12, 2025

Geode Capital Management LLC Sells 12,160 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jan 12, 2025
pulisher
Jan 12, 2025

Analysts Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80 - Defense World

Jan 12, 2025
pulisher
Jan 10, 2025

Immuneering (NASDAQ:IMRX) Earns Buy Rating from Chardan Capital - Defense World

Jan 10, 2025
pulisher
Jan 10, 2025

Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

3 Penny Stocks to Watch Now, 1/9/25 - TipRanks

Jan 09, 2025
pulisher
Jan 08, 2025

Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan Capital - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Immuneering reports promising mid-stage readout for pancreatic cancer therapy - FirstWord Pharma

Jan 08, 2025
pulisher
Jan 07, 2025

Wall Street-Heavily Traded - WDRB

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering announce data update from Phase 2a trial of IMM-1-104 - TipRanks

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Why Is Immuneering Stock Trading Higher On Tuesday? - AOL

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering touts positive pancreatic cancer data for MEK inhibitor - Endpoints News

Jan 07, 2025
pulisher
Jan 07, 2025

Exciting Cancer Therapy Breakthrough! Immuneering’s New Trial Results Amaze - elblog.pl

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering Corp reports promising clinical trial data - Investing.com India

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering Surges Amid Promising Trial Data! What’s Driving the Surge? - Reporteros del Sur -

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms - Markets Insider

Jan 07, 2025
pulisher
Jan 07, 2025

Pre-Market Boost For Immuneering (IMRX) As Trial Data Impresses Investors - Stocks Telegraph

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering stock jumps on lead asset data (IMRX:NASDAQ) - Seeking Alpha

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering stock soars on promising pancreatic cancer trial results By Investing.com - Investing.com South Africa

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering stock soars on promising pancreatic cancer trial results - Investing.com India

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering (IMRX) Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms - StreetInsider.com

Jan 07, 2025
pulisher
Jan 07, 2025

Immuneering Announces Positive Data Update from Three - GlobeNewswire

Jan 07, 2025
pulisher
Dec 30, 2024

Immuneering Co. (NASDAQ:IMRX) Sees Large Growth in Short Interest - MarketBeat

Dec 30, 2024
pulisher
Dec 27, 2024

HighTower Advisors LLC Increases Stock Holdings in Immuneering Co. (NASDAQ:IMRX) - Defense World

Dec 27, 2024
pulisher
Dec 19, 2024

Immuneering Forms Elite Advisory Board After FDA Fast Track Win for Pancreatic Cancer Drug - StockTitan

Dec 19, 2024
$79.89
price up icon 2.27%
$32.25
price up icon 1.67%
$4.47
price down icon 5.10%
$353.31
price up icon 2.22%
biotechnology ONC
$221.22
price up icon 0.71%
$114.50
price down icon 0.67%
Cap:     |  Volume (24h):